Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Breast Cancer
BREAST CANCER ADVISOR
FEATURED CONTENT
-
-
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated. -
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions. -
FDA Guidance on Surrogate Endpoints Lacks Specificity
Treatment effects of pathologic CR, DFS, ORR, and PFS were not strongly correlated with treatment effects on overall survival. -
Clinical Utility of Deep Phenotyping and Whole-Genome Risk Assessment in Early Cancer Detection and Precision Oncology
State-of-the-art advanced imaging coupled with whole-genome sequencing shows utility in early cancer detection and cancer-associated pathogenic variant detection.
VIDEO SERIES
The Phase 3 PlanB Trial
Continue to Work?
Drug Resistance to CDK4/6 Inhibitors
Comparing Ribociclib and Palbociclib
Ribociclib, Abemaciclib, and Palbociclib
The Potential of CDK4/6 Inhibitors
How Cyclin D Plays A Role
2016 SABCS: Clinical Insights Telli
2016 SABCS: Clinical Insights Oregan
HER2-positive Metastatic and TNBC
Frontline Treatments
Treatment-related Neuropathy
ER-positive, HER2-negative
Emerging Medicines
Triple-negative Breast Cancer
Insights from the Lab and Clinic
Trastuzumab Resistance
Biologic Role of HER2
Strategies in Management
BREAST CANCER NEWS
Tucatinib-Containing Regimen Prolongs Overall Survival in Breast Cancer Characterized by Brain Metastases
Alpelisib Plus Fulvestrant Demonstrates Efficacy in PIK3CA-Mutated, HR+, HER2- Breast Cancer After CDK4/6 Inhibitor
18F-FDG-PET Response-Adapted Strategy For De-Escalation of Neoadjuvant Therapy in Patients With Early-Stage, HER2-Positive Breast Cancer
TRAIN-2 Highlights Questions Around the Use of Anthracycline-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Are Patients With Ductal Carcinoma In Situ Being Overtreated?
Want to read more?
Please login or register first to view this content.
